Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.

Glund S, Coble K, Gansser D, Stangier J, Hoermann K, Pollack CV, Reilly P.

J Thromb Haemost. 2019 Aug;17(8):1319-1328. doi: 10.1111/jth.14476. Epub 2019 Jun 18.

2.

Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.

Yasaka M, Ikushima I, Harada A, Imazu S, Taniguchi A, Norris S, Gansser D, Stangier J, Schmohl M, Reilly PA.

Res Pract Thromb Haemost. 2017 Aug 5;1(2):202-215. doi: 10.1002/rth2.12029. eCollection 2017 Oct.

3.

Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.

Stopfer P, Giessmann T, Hohl K, Hutzel S, Schmidt S, Gansser D, Ishiguro N, Taub ME, Sharma A, Ebner T, Müller F.

Br J Clin Pharmacol. 2018 Sep;84(9):1941-1949. doi: 10.1111/bcp.13609. Epub 2018 Jun 21.

4.

Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail.

Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, Jungnik A, Gansser D, Ebner T, Müller F.

Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):69-80. doi: 10.1007/s13318-017-0427-9.

5.

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.

Wiebe S, Schnell D, Külzer R, Gansser D, Weber A, Wallenstein G, Halabi A, Conrad A, Wind S.

Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):461-469. doi: 10.1007/s13318-016-0359-9.

6.

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.

Glund S, Stangier J, van Ryn J, Schmohl M, Moschetti V, Haazen W, De Smet M, Gansser D, Norris S, Lang B, Reilly P, Kreuzer J.

Clin Pharmacokinet. 2017 Jan;56(1):41-54. doi: 10.1007/s40262-016-0417-0.

7.

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin.

Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, Zimdahl-Gelling H, Gansser D, Wein M, Ebner T, Müller F.

Clin Pharmacol Ther. 2016 Sep;100(3):259-67. doi: 10.1002/cpt.406. Epub 2016 Jul 29.

8.

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers.

Glund S, Stangier J, van Ryn J, Schmohl M, Moschetti V, Haazen W, De Smet M, Gansser D, Norris S, Lang B, Reilly P, Kreuzer J.

J Am Coll Cardiol. 2016 Apr 5;67(13):1654-1656. doi: 10.1016/j.jacc.2016.01.043. No abstract available.

9.

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J.

Lancet. 2015 Aug 15;386(9994):680-90. doi: 10.1016/S0140-6736(15)60732-2. Epub 2015 Jun 15.

PMID:
26088268
10.

Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.

Schmohl M, Gansser D, Moschetti V, Stangier J.

Thromb Res. 2015 Mar;135(3):532-6. doi: 10.1016/j.thromres.2014.12.021. Epub 2015 Jan 2.

PMID:
25600440
11.

Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.

Fuchs H, Kishimoto W, Gansser D, Tanswell P, Ishiguro N.

Drug Metab Dispos. 2014 Oct;42(10):1761-5. doi: 10.1124/dmd.114.058545. Epub 2014 Jul 22.

PMID:
25053619
12.

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.

Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, Stopfer P, Wind S, Petersen-Sylla M, Halabi A, Koenen R.

Cancer Chemother Pharmacol. 2014 Aug;74(2):267-75. doi: 10.1007/s00280-014-2484-y. Epub 2014 Jun 7.

13.

Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.

Wind S, Giessmann T, Jungnik A, Brand T, Marzin K, Bertulis J, Hocke J, Gansser D, Stopfer P.

Clin Drug Investig. 2014 Mar;34(3):173-82. doi: 10.1007/s40261-013-0161-2.

PMID:
24399452
14.

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.

Stopfer P, Marzin K, Narjes H, Gansser D, Shahidi M, Uttereuther-Fischer M, Ebner T.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1051-61. doi: 10.1007/s00280-011-1803-9. Epub 2011 Dec 27.

PMID:
22200729
15.

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Stangier J, Rathgen K, Stähle H, Gansser D, Roth W.

Br J Clin Pharmacol. 2007 Sep;64(3):292-303. Epub 2007 May 15.

16.

Interaction of lignans with human sex hormone binding globulin (SHBG).

Schöttner M, Gansser D, Spiteller G.

Z Naturforsch C J Biosci. 1997 Nov-Dec;52(11-12):834-43.

PMID:
9463941
17.

Lignans interfering with 5 alpha-dihydrotestosterone binding to human sex hormone-binding globulin.

Schöttner M, Spiteller G, Gansser D.

J Nat Prod. 1998 Jan;61(1):119-21.

PMID:
9461660
18.

Lignans from the roots of Urtica dioica and their metabolites bind to human sex hormone binding globulin (SHBG).

Schöttner M, Gansser D, Spiteller G.

Planta Med. 1997 Dec;63(6):529-32.

PMID:
9434605
20.

Aromatase inhibitors from Urtica dioica roots.

Gansser D, Spiteller G.

Planta Med. 1995 Apr;61(2):138-40.

PMID:
17238068
21.

Supplemental Content

Loading ...
Support Center